Allogene Therapeutics (ALLO) stake: Belldegrun group reports 3.9% ownership

Rhea-AI Filing Summary

Allogene Therapeutics, Inc. reports that investor and director Arie Belldegrun and affiliated entities have amended their passive ownership report. As of May 11, 2026, Dr. Belldegrun beneficially owns 13,610,578 shares of Allogene common stock, representing 3.9% of the 345,154,561 shares outstanding. His total includes 4,010,524 shares issuable within 60 days upon exercise of stock options and shares held through Bellco Legacy entities and Vida Ventures funds. The filing confirms that each reporting person now owns 5% or less of the outstanding common stock, with joint filing across the listed entities.

Key Figures

Belldegrun beneficial ownership: 13,610,578 shares Ownership percentage: 3.9% Shares outstanding: 345,154,561 shares +4 more

7 metrics

Belldegrun beneficial ownership 13,610,578 shares Total Allogene common stock beneficially owned, representing 3.9% of the class

Ownership percentage 3.9% Belldegrun’s beneficial ownership of Allogene common stock based on shares outstanding

Shares outstanding 345,154,561 shares Allogene common stock outstanding as of May 11, 2026, used for percentage calculations

Stock options exercisable 4,010,524 shares Shares issuable within 60 days of June 30, 2026 upon exercise of options held by Belldegrun

Bellco Legacy IV LLC holdings 4,710,120 shares Allogene common stock beneficially owned by Bellco Legacy IV LLC (about 1.3% of the class)

Bellco Legacy LLC holdings 539,867 shares Allogene common stock beneficially owned by Bellco Legacy LLC (about 0.2% of the class)

Vida Ventures LLC holdings 1,798,163 shares Allogene common stock beneficially owned by Vida Ventures LLC (0.5% of the class)

Key Terms

beneficial ownership, sole voting power, shared dispositive power, pecuniary interest, +1 more

5 terms

beneficial ownership financial

"Row 9 of each Reporting Person's cover page sets forth the aggregate number of shares beneficially owned"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

sole voting power financial

"5 | Sole Voting Power 4,838,291.00 6 | Shared Voting Power 8,772,287.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

shared dispositive power financial

"8 | Shared Dispositive Power 8,772,287.00 9 13,610,578.00"

pecuniary interest financial

"Dr. Belldegrun disclaims beneficial ownership of the shares held by Vida, except to the extent of any pecuniary interest"

Schedule 13(d) of the Exchange Act regulatory

"other than for the purpose of determining his obligations under Section 13(d) of the Exchange Act"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 08:20 PM Accepted by SEC EDGAR 08/07/2026 - 08:20 PM Learn about SEC filing dates

FAQ

What percentage of Allogene Therapeutics (ALLO) does Arie Belldegrun report owning?

Arie Belldegrun reports beneficial ownership of 3.9% of Allogene Therapeutics’ common stock, totaling 13,610,578 shares, based on 345,154,561 shares outstanding as of May 11, 2026.

How many Allogene (ALLO) shares are included from stock options held by Arie Belldegrun?

The reported beneficial ownership for ALLO includes 4,010,524 shares of common stock issuable within 60 days of June 30, 2026 upon the exercise of stock options held by Arie Belldegrun.

What is the total Allogene (ALLO) stake held through Bellco Legacy entities?

Bellco Legacy IV LLC reports 4,710,120 shares (about 1.3%), and Bellco Legacy LLC reports 539,867 shares (about 0.2%) of Allogene common stock, all counted in Arie Belldegrun’s aggregate beneficial ownership.

How many Allogene (ALLO) shares are reported by the Vida Ventures entities?

Vida Ventures LLC reports 1,798,163 shares, Vida Ventures III, L.P. 1,720,172 shares, and Vida Ventures III-A, L.P. 3,965 shares of Allogene common stock, all treated as beneficially owned for Section 13(d) purposes.

Are the reporting persons in this Allogene (ALLO) Schedule 13G/A over or under 5% ownership?

Each reporting person, including Arie Belldegrun and the affiliated Bellco and Vida entities, certifies ownership of 5 percent or less of Allogene’s outstanding common stock in this amended beneficial ownership report.

What share count did Allogene (ALLO) use to calculate ownership percentages in this filing?

Ownership percentages are calculated using 345,154,561 shares of Allogene common stock outstanding as of May 11, 2026, as stated in the company’s Quarterly Report on Form 10-Q.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 11)

Allogene Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

019770106

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 019770106

1

Names of Reporting Persons

Arie Belldegrun, M.D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,838,291.00
6	Shared Voting Power 8,772,287.00
7	Sole Dispositive Power 4,838,291.00
8	Shared Dispositive Power 8,772,287.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,610,578.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.9 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 019770106

1

Names of Reporting Persons

Bellco Legacy LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 539,867.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 539,867.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

539,867.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.2 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 019770106

1

Names of Reporting Persons

Bellco Legacy IV LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,710,120.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,710,120.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,710,120.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 019770106

1

Names of Reporting Persons

Vida Ventures LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEVADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,798,163.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,798,163.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,798,163.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.5 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 019770106

1

Names of Reporting Persons

Vida Ventures III, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEVADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,720,172.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,720,172.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,720,172.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.5 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 019770106

1

Names of Reporting Persons

Vida Ventures III-A, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEVADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,965.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,965.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,965.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Allogene Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 210 East Grand Avenue, South San Francisco, CA, 94080.
Item 2.
(a)	Name of person filing: Arie Belldegrun Bellco Legacy LLC Bellco Legacy IV LLC Vida Ventures LLC Vida Ventures III, L.P. Vida Ventures III-A, L.P.
(b)	Address or principal business office or, if none, residence: Arie Belldegrun: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067 Bellco Legacy LLC: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067 Bellco Legacy IV LLC: 10100 Santa Monica Blvd., 15th Floor, Los Angeles, CA 90067 Vida Ventures LLC: 40 Broad Street, #201, Boston, MA 02109 Vida Ventures III, L.P.: 40 Broad Street, #201, Boston, MA 02109 Vida Ventures III-A, L.P.: 40 Broad Street, #201, Boston, MA 02109
(c)	Citizenship: Arie Belldegrun: United States and Israel Bellco Legacy LLC: Delaware Bellco Legacy IV LLC: Delaware Vida Ventures LLC: Nevada Vida Ventures III, L.P.: Nevada Vida Ventures III-A, L.P.: Nevada
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 019770106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 9 of Dr. Belldegrun's cover page includes 4,010,524 shares of common stock issuable within 60 days of June 30, 2026 upon the exercise of stock options held by the Reporting Person and also includes (a) 4,710,120 shares of common stock beneficially owned by Bellco Legacy IV LLC, a limited liability company managed by Dr. Belldegrun and Rebecka Belldegrun, (b) 539,867 shares of common stock beneficially owned by Bellco Legacy LLC, a limited liability company owned and managed by trusts controlled by Dr. Belldegrun and Rebecka Belldegrun, (c) 1,798,163 shares of common stock beneficially owned by Vida Ventures LLC (Vida), a limited liability company of which VV Manager LLC is the manager, of which Dr. Belldegrun is a Senior Managing Director, (d) 1,720,172 shares of common stock beneficially owned by Vida Ventures III, L.P. (Vida III), a limited partnership of which Vida Ventures GP III, LLC (Vida GP III) is the manager, of which Dr. Belldegrun is a Senior Managing Director, and (e) 3,965 shares of common stock beneficially owned by Vida Ventures III-A, L.P. (Vida III-A), a limited partnership of which Vida GP III is the manager, of which Dr. Belldegrun is a Senior Managing Director. Dr. Belldegrun disclaims beneficial ownership of the shares held by Vida, Vida III and Vida III-A, except to the extent of any pecuniary interest therein, and other than for the purpose of determining his obligations under Section 13(d) of the Exchange Act.
(b)	Percent of class: Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. This percentage is calculated based on 345,154,561 shares of common stock outstanding as of May 11, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed on May 13, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.
	(ii) Shared power to vote or to direct the vote: Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.
	(iii) Sole power to dispose or to direct the disposition of: Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.
	(iv) Shared power to dispose or to direct the disposition of: Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Arie Belldegrun, M.D.

Signature:	/s/ Arie Belldegrun
Name/Title:	Arie Belldegrun, M.D.
Date:	08/07/2026

Bellco Legacy LLC

Signature:	/s/ Arie Belldegrun
Name/Title:	By Arie Belldegrun, M.D., Manager
Date:	08/07/2026

Bellco Legacy IV LLC

Signature:	/s/ Arie Belldegrun
Name/Title:	By Arie Belldegrun, M.D., Manager
Date:	08/07/2026

Vida Ventures LLC

Signature:	/s/ Arie Belldegrun
Name/Title:	By VV Manager LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director
Date:	08/07/2026

Vida Ventures III, L.P.

Signature:	/s/ Arie Belldegrun
Name/Title:	By Vida Ventures GP III, LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director
Date:	08/07/2026

Vida Ventures III-A, L.P.

Signature:	/s/ Arie Belldegrun
Name/Title:	By Vida Ventures GP III, LLC, its Manager, By Arie Belldegrun, M.D., Senior Managing Director,
Date:	08/07/2026

Exhibit Information

Joint Filing Agreement